Structural neural plasticity evoked by rapid-acting antidepressant interventions
- PMID: 39558048
- PMCID: PMC11892022
- DOI: 10.1038/s41583-024-00876-0
Structural neural plasticity evoked by rapid-acting antidepressant interventions
Erratum in
-
Publisher Correction: Structural neural plasticity evoked by rapid-acting antidepressant interventions.Nat Rev Neurosci. 2025 Feb;26(2):135. doi: 10.1038/s41583-024-00894-y. Nat Rev Neurosci. 2025. PMID: 39668187 No abstract available.
Abstract
A feature in the pathophysiology of major depressive disorder (MDD), a mood disorder, is the impairment of excitatory synapses in the prefrontal cortex. Intriguingly, different types of treatment with fairly rapid antidepressant effects (within days or a few weeks), such as ketamine, electroconvulsive therapy and non-invasive neurostimulation, seem to converge on enhancement of neural plasticity. However, the forms and mechanisms of plasticity that link antidepressant interventions to the restoration of excitatory synaptic function are still unknown. In this Review, we highlight preclinical research from the past 15 years showing that ketamine and psychedelic drugs can trigger the growth of dendritic spines in cortical pyramidal neurons. We compare the longitudinal effects of various psychoactive drugs on neuronal rewiring, and we highlight rapid onset and sustained time course as notable characteristics for putative rapid-acting antidepressant drugs. Furthermore, we consider gaps in the current understanding of drug-evoked in vivo structural plasticity. We also discuss the prospects of using synaptic remodelling to understand other antidepressant interventions, such as repetitive transcranial magnetic stimulation. Finally, we conclude that structural neural plasticity can provide unique insights into the neurobiological actions of psychoactive drugs and antidepressant interventions.
© 2024. Springer Nature Limited.
Conflict of interest statement
Competing interests: A.C.K. has been a scientific adviser or consultant for Boehringer Ingelheim, Empyrean Neuroscience, Freedom Biosciences, and Psylo. A.C.K. has received research support from Intra-Cellular Therapies. C. Liston has served as a scientific adviser or consultant for Brainify.AI, Compass Pathways, Delix Therapeutics, and Magnus Medical. The other authors report no competing interests.
References
-
- DeFelipe J & Farinas I The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs. Prog Neurobiol 39, 563–607 (1992). - PubMed
-
- Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N & Nakahara H Structure-stability-function relationships of dendritic spines. Trends Neurosci 26, 360–368 (2003). - PubMed
-
- Robinson TE & Kolb B Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47, 33–46 (2004). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous